Abstract

L-arginine (L-ARG)-nitric oxide (NO)–cGMP (cyclic guanosine monophosphate) cycle has been determined in various studies to be associated with epilepsy. Tadalafil is a potent inhibitor of phosphodiesterase 5 (PDE5) and increases the level of cGMP. Methylene blue (MB) is a lipophilic agent regulating intracellular electron flow as well as increasing the mitochondrial effectiveness. It also decreases cGMP levels by directly inhibiting guanylate cyclase.The aim of the present study was to evaluate the effects of MB and tadalafil on pentylenetetrazol-induced seizures. MB and tadalafil were administered 30 min prior to PTZ (70 mg/kg, i.p.) injection and the dose-response ratio was determined. Racine's Convulsion Scale and first myoclonic jerk (FMJ) onset time was used to evaluate seizures. Besides, drugs were administered 30 min prior to pentylenetetrazol (35 mg/kg, i.p.) injection and EEG was recorded from cortex and the spike wave discharges was determined in EEG. Plasma cGMP levels were measured in all groups. 5 and 10 mg/kg MB decreased Racine convulsion stage, increased FMJ onset time and decreased cGMP levels when compared with saline. 10 mg/kg tadalafil increased cGMP levels and Racine convulsion stage but decreased FMJ onset time compared with saline. Spike wave discharges were decreased in 5 and 10 mg/kg MB groups and increased in 10 mg/ kg tadalafil group when compared with saline group.The proconvulsant properties of all the agents may be taken into consideration, especially when prescribing PDE5 inhibitors.

Details

Title
The Effects of Methylene Blue and Tadalafil in Pentylenetetrazole Induced Convulsion Model
Author
Solmaz, Volkan; Aksoy, Durdane; Yurtogulları, Sukran; Semiz, Murat; Aydemir, Emre; Erbas, Oytun
Pages
286-290
Section
Research
Publication year
2016
Publication date
Sep 2016
Publisher
Gulhane Medical Journal
ISSN
13020471
e-ISSN
21468052
Source type
Scholarly Journal
Language of publication
English; Turkish
ProQuest document ID
2440111696
Copyright
© 2016. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.